Hope Rugo: Great to have more effective ADCs for breast cancer treatment
Hope Rugo, Professor of medicine at the University of California San Francisco, shared a post on X:
“SHR-A1811 new HER2 ADC with topo1 inhib payload similar pCR rate in HER2+ BC compared to TCbHP in the fascinate trial in Shanghai.
One Gr2 ILD. Pyrotonib only added tox.
One agent equal to 3-4? Not powered for EFS. Great to have more effective ADCs!!”
Dr. Hope Rugo, is a professor of medicine at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. With experience in hematology and oncology, she specializes in breast cancer treatment and clinical trials.
Dr. Rugo’s research focuses on innovative therapies and combination treatments to improve outcomes for breast cancer patients, including immunotherapy and targeted agents. She is known for her contributions to reducing treatment toxicity educating through initiatives like the Breast Forum.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023